ImmunityBio, Inc. Stock Prediction and Forecast [IBRX]

AI-generated source summary

ImmunityBio (IBRX) is showing strong bullish signals across short-term and long-term moving averages, with a positive forecast for the stock. A general buy signal is also present due to the short-term average being above the long-term average. Key support levels are identified at $8.46 and $5.78, with breakdowns below these levels signaling a sell. A pivot bottom point on February 5, 2026, led to a 104.79% rise. A 3-month MACD buy signal indicates further potential upside. However, declining volume on the last trading day, despite gaining prices, suggests a divergence and a potential early warning. The stock's price action over the past three months has been positive, with a projected increase of 273.27% over the next three months and a significant 12.76% average daily gain. Long-term analysis suggests a potential increase of 65.67% over the next year. The stock exhibits high volatility, with its RSI at 80, indicating a very high risk. Analyst ratings are mixed, with some recommending 'buy' and others 'sell' or 'overweight', but the overall consensus points to a 'hold' or 'accumulate' stance. The stock's P/E ratio is negative at -27.69, suggesting potential financial difficulties or reinvestment for growth. Key trading levels for short-term and long-term are identified, with a buy signal from the 3-month MACD and a pivot bottom. The stock is currently trading above key moving averages, signaling bullish momentum. Support is found at $9.83, and resistance is identified at $11.58, $12.68, and $13.14.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   25 Feb 2026, 04:15 UTC

   The analyst published the original source item.

2. First prediction resolved

   25 Feb 2026, 16:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   25 Feb 2026, 16:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:24 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.